The former head of Valeant Pharmaceuticals International Inc.’s dermatology division was unable to convince a court to rethink the validity of a class action lawsuit accusing the generic drugmaker and its executives of engaging in a massive scheme to fraudulently inflate the company’s stock prices.
Deborah Jorn, who oversaw Valeant’s U.S. dermatology business for more than two years, had moved for reconsideration in New Jersey federal court of an April ruling denying her motion to dismiss the case.
